NRGN and Alzheimer disease: To verify the contribution of clinical diagnosis to the CSF catecholamine levels and to examine other factors, regression analyses were performed with in addition to clinical diagnosis, CSF Aβ42 and P-tau as markers of AD neuropathology and neurogranin as a marker of AD related synaptic damage.